$BOLD

TANG KEVIN purchased $222K of BOLD (indirect holdings)

TANG KEVIN purchased 91,585 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.42 ($2.42–$2.48, $0.22M total) across 3 trades over 2026-07-09 to 2026-07-13.

Original reporting
SEC EDGAR · TANG KEVIN
Published Jul 13, 2026, 11:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 13, 2026, 11:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$BOLD
Bullish
medium confidence
Mentioned
$BOLD
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BOLDBullishLow
01

Why it matters

The newest concrete fact is the disclosed open-market purchase by a 10% owner over July 9-13 at an average price of $2.4247, totaling about $222.1k.

02

Market read

Primarily sentiment and positioning information from an insider transaction, with limited standalone trading catalyst value.

03

What to watch

No accompanying operational update is provided, so traders should avoid extrapolating this purchase into near-term fundamental expectations.

Relevance 5/10Novelty 5/10Timing: Filed July 13, after-hours, covering purchases from July 9-13

Background

The article is an SEC Form 4 insider transaction disclosure for Boundless Bio, Inc. (BOLD).

Company-level read

Ticker impact

$BOLDBullishMedium confidence
Context

SEC Form 4 shows 10% owner Tang Kevin bought 91,585 shares of Boundless Bio at about $2.42 to $2.48 between July 9-13.

Expected impact

Near-term impact likely limited, with any effect more sentiment-driven than fundamental.

Evidence & confidence

The filing is primary-source and time-stamped, but it is an indirect holding purchase without accompanying guidance, trial, or deal news.

Market effects

No sector-level signal; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Indirect holdings and lack of a 10b5-1 plan detail can reduce interpretability; buying may reflect liquidity or portfolio mechanics rather than a new outlook.

Key entities

  • Boundless Bio, Inc.

    Company whose shares were purchased; subject of the Form 4 disclosure.

  • Tang Kevin

    10% owner reporting indirect open-market purchases via Form 4.

Related articles